Riskpilot← Back to searchSign inGet full accessEpoqe Pharma ApS
APSActiveCVR 42443670Nordre Fasanvej 215Research and experimental development on natural sciences and engineering · NACE 7210Est. 20215 employeeswww.epoqepharma.com
Revenue 2025
DKK -8,6M
-37% vs 2025
EBITDA margin
128.0%
+35% vs 2025
Equity ratio
89.8%
Financial strength
Net profit 2025
DKK -9,1M
+35% vs 2025
| Revenue | DKK -8,6M | -37% |
| EBITDA | DKK -11M | +35% |
| Net profit | DKK -9,1M | +35% |
| Total assets | DKK 49,2M | +41% |
| Equity | DKK 44,1M | +47% |
| Employees | 5 | — |
Legal name
Epoqe Pharma ApS
CVR number
42443670
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4. juni 2021
Share capital
DKK 288.886
Employees
5 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at udvikle og markedsføre et eller flere lægemidler, herunder at drive forskning med henblik på at identificere, validere, udvikle og markedsføre lægemidler tillige med anden virksomhed, der står i forbindelse hermed.
Address
Nordre Fasanvej 215
Phone
+4526343323
Website
www.epoqepharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|
| Revenue | -17 | -19 | 1.273 | -13.720 | -8.599 |
| Staff expenses | -0 | -0 | -1.446 | -3.173 | -2.406 |
| EBITDA | -17 | -19 | -173 | -16.893 | -11.006 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -17 | -19 | -173 | -16.893 | -11.006 |
| Net financials | -1 | -0 | -1 | 199 | 42 |
| Profit before tax | -18 | -20 | -174 | -16.695 | -10.964 |
| Tax | -0 | -4 | -38 | -2.751 | -1.914 |
| Net profit | -18 | -15 | -136 | -13.944 | -9.050 |
| Item | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|
| Total assets | 145 | 2.580 | 1.111 | 34.851 | 49.150 |
| Equity | 133 | 118 | -18 | 30.042 | 44.145 |
| Long-term debt | 0 | 2.443 | 860 | 0 | 0 |
| Short-term debt | 12 | 19 | 270 | 4.808 | 5.005 |
| Total debt | 12 | 2.462 | 1.129 | 4.808 | 5.005 |
EBITDA margin
-1100559400.0%
This company
15.8%
Market median
-6965565923% vs market
20222025
Equity ratio
89.8%
This company
38.2%
Market median
+135% vs market
20222025
Return on equity
-20.5%
This company
18.4%
Market median
-211% vs market
20222025
Net profit margin
-905041500.0%
This company
8.1%
Market median
-11173351952% vs market
20222025
Asset turnover
-0.17×
This company
1.12×
Market median
-115% vs market
20222025
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20222025
- Annual report 2025Filed via CVR / Virk · Period 2025-07-01 – 2025-12-31
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-06-04 – 2022-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AS Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
JT Management | Management | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2025 | |
LUNDBECKFOND INVEST A/S | Company | 20.0% | 20.0% | 2025 |
Helms & Sams ApS | Company | 10.0% | 10.0% | 2025 |
Edvince ApS | Company | 5.0% | 5.0% | 2024 |
CMCGreenhouse ApS | Company | 5.0% | 5.0% | 2025 |
Biologik ApS | Company | 33.3% | 33.3% | 2021 |
Thomsen Pharma ApS | Company | 5.0% | 5.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LUNDBECKFONDEN
Epoqe Pharma ApS Board members of Epoqe Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anette Sams Nielsen | Chief Executive Officer | 0 companies |
| Jens Thostrup Bukrinski | Management | 0 companies |
| Jan Bjerrum Bach | Chairman | 0 companies |
| Alejandra Maria Cristina Bonifacini Mørk | Board of Directors | 0 companies |
| Lars Gredsted | Board of Directors | 0 companies |
| Henrijette Elsebeth Richter | Board of Directors | 0 companies |
| Anders Gaarsdal Holst | Chairman | 0 companies |